Rajgor Amarkumar, Hurley Rhona, Douglas Catriona M, Paterson Claire, Moor James, Lester Shane, Sionis Sara, Davies Katharine, O'Hara James, Inman Gareth, Jones Terry, Hamilton David Winston
National Institute for Health & Care Research Doctoral Fellow in Otolaryngology, Population Health Sciences Institute, Newcastle University, Newcastle-Upon-Tyne, UK.
Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle-Upon-Tyne, UK.
Clin Otolaryngol. 2025 Mar;50(2):344-351. doi: 10.1111/coa.14260. Epub 2024 Dec 11.
Historically, 15% of laryngeal cancer patients undergo non-curative management, but pragmatic data on this group are limited. This information is crucial to help patients make informed decisions about their care. Supported by the Northern Head & Neck Alliance, this retrospective study is the first to present survival outcomes for non-curative laryngeal cancer patients in Northern UK.
Retrospective data were compiled for patients with laryngeal squamous cell cancer from five large tertiary head and neck centres in Northern UK (Newcastle, Glasgow, Sheffield, Leeds, and Middlesbrough). The collected data encompassed demographic details, treatment and clinical outcomes.
Among 373 patients, the mean age was 72, and 73% were male. The median follow-up was 6 months. 17% had early-stage (T1-2), and 83% had late-stage (T3-4) disease. By data collection, 99% had died. The mean survival time (MST) was 9.1 months. Patients with metastases had an MST of 6.9 months, while those without had 9.4 months. Early-stage patients had an MST of 13.3 months, compared to 8.2 months for advanced disease. By subsite, MSTs were 8.2 months for supraglottic, 12.5 for glottic, 5.5 for subglottic, and 7.9 for transglottic cancers.
This study stands as the first to explore survival outcomes in laryngeal cancer patients undergoing non-curative management. The findings can provide valuable insights for informing patients about survival in the absence of radical treatment, facilitating important decision-making conversations.
从历史数据来看，15%的喉癌患者接受的是非根治性治疗，但关于这一群体的实际数据有限。这些信息对于帮助患者做出明智的治疗决策至关重要。在北部头颈联盟的支持下，这项回顾性研究首次呈现了英国北部非根治性喉癌患者的生存结果。
收集了来自英国北部五个大型三级头颈中心（纽卡斯尔、格拉斯哥、谢菲尔德、利兹和米德尔斯堡）的喉鳞状细胞癌患者的回顾性数据。收集的数据包括人口统计学细节、治疗情况和临床结果。
在373名患者中，平均年龄为72岁，73%为男性。中位随访时间为6个月。17%为早期（T1 - 2）患者，83%为晚期（T3 - 4）患者。到数据收集时，99%的患者已经死亡。平均生存时间（MST）为9.1个月。有转移的患者MST为6.9个月，无转移的患者为9.4个月。早期患者的MST为13.3个月，晚期患者为8.2个月。按亚部位划分，声门上癌的MST为8.2个月，声门癌为12.5个月，声门下癌为5.5个月，跨声门癌为7.9个月。
本研究是首次探索接受非根治性治疗的喉癌患者生存结果的研究。这些发现可为告知患者在未进行根治性治疗情况下的生存情况提供有价值的见解，有助于开展重要的决策讨论。
